65,437 trials
Gliosarcoma · MGMT-Unmethylated Glioblastoma
Primary: Progression-free Survival (PFS) (Phase II) — 8.5; 7.7 months — p=0.96
Fluid Loss · Dialysis
Primary: Average Relative Index Value Following a Hemodialysis Procedure — 93.05 Relative Index (RI)
Hepatitis C · Human Immunodeficiency Virus
Primary: The Change in Hepatitis C Viral Load From Baseline to 4 Weeks of Maraviroc or No Maraviroc — 2035071; 2027648; 2082302; 1216383 International Units/ml — p=0.13
Post Covid-19 Patients
Primary: Fatigue Assessment Scale (FAS) — 31.32; 28.42; 14.90; 15.3 Total score (1 to 5 point scale)
Attention-Deficit/Hyperactivity Disorder (ADHD)
Primary: Incidence of Adverse Events During 8 Weeks of Adjunct SPN-812 Treatment — 55.4 percent of subjects
Major Depressive Disorder
Primary: Amygdala-PCC Functional Connectivity — -0.0815; -0.0530; -0.0456 z-score — p=.195
Missing Teeth
Primary: Percentage of New Vital Bone. — 16.33; 26.11; 30.5; 39.67 percentage of new vital bone
Dry Eye
Primary: Change in Overall Quality of Ocular Comfort From Baseline to 30-Day Follow-Up Using VAS Scores — 18.47; 9.65 Scores on a scale
Hypothermia
Primary: Temperature at Arrival to Warmer — 36.9; 37.0 degrees Celsius
Rectal Carcinoma · Rectosigmoid Carcinoma
Primary: Bowel Function — 30.8; 29.5 MSK-BFI score on a scale (range 18-90)
Acute Respiratory Distress Syndrome
Primary: DARE (Daytime Activity Ratio Estimate), Post Extubation — 56.7; 61.7 Percentage of total activity
Periodontitis
Primary: Periodontal Probing Depth — 2.5; 3.2; 3.4 millimeter
Endometriosis
Primary: Dysmenorrhea — 62; 101; 32; 43 Participants
Psoriasis
Primary: Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at…
Psoriasis Vulgaris
Primary: Psoriasis Area and Severity Index (PASI) Score — 3.9 score on a scale